<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED7DFA83-26A3-4280-9A85-FEFBEF19AB03"><gtr:id>ED7DFA83-26A3-4280-9A85-FEFBEF19AB03</gtr:id><gtr:firstName>Aine</gtr:firstName><gtr:surname>McKnight</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G117%2F547"><gtr:id>064C5592-F916-47BD-A4A7-66C1AB7FC779</gtr:id><gtr:title>Identification of and molecular characterisation of a HIV restriction factor Lv2</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G117/547</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The purpose of this Fellowship is to understand an anti-HIV activity Lv-2 in human cells. I propose an analysis of the cellular and molecular mechanisms underlying this restriction. That is we will
(1)Characterise how the viral genes, capsid (CA) and envelope (Env), avoid the factor. We have expertise on functional Env studies. For CA studies we will collaborate with Wes Sundquist an expert on viral CA. Also to develop techniques to analyse CA we will collaborate with Peter Stockley to make fluorescent aptamer probes to visualise CA microscopically.
(2) Identify the human gene that encodes this antiviral factor by screening logical candidate genes in collaboration with Prof Joe Sodroski who cloned TRIM5 (responsible for anti-viral factor Lv-1) and Dr Germana Meroni an expert on the TRIM family of proteins. Also we will search libraries of human genes. 
(3) Investigate the pathways HIV takes to get from the plasma membrane to the nucleus. There are a number of routes by which viruses can traffic trough cells. Our data suggest that HIV can take at least two and that the potency of Lv-2 is dependent on the route taken. With Prof. Mark Marsh we will determine the restrictive and non-restrictive routes taken by HIV using dominate mutants and siRNA. Scientific and medical opportunities: The results will contribute to our understanding of HIV replication and pathogenesis, and to innate immunity to viral infection. They will also contribute to the understanding of trafficking of cell components and may suggest novel targets for the design and delivery of drugs to treat HIV.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1807520</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Center of the Cell series 'The big question'</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FFA86896-E144-43E5-ABD2-5EBB88C6FB9B</gtr:id><gtr:impact>The developemtn of the lecture involves two workshops with 6th form students from the local area. The lecturer (me) discusses science and the students feedback on what is interesting to them. The activity engages both the scientist and the student in science at a 'public' level.

Sixth form teachers and teachers continue to come back every year.</gtr:impact><gtr:outcomeId>fx3wYLnTsom</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>90BBF578-B914-4F03-81F0-3206CBFC370C</gtr:id><gtr:impact>The Centre of the Cell is a visitor centre in The Blizard Institute for Cell and Molecular Biology, Barts &amp;amp; The London Medical School, Queen Mary University of London. http://www.centreofthecell.org/ 
All of the scientific content in Centre of the Cell is based on the cutting edge medical research going on at Queen Mary and its Medical School. Everyone featured in the films is an employee either of Queen Mary or the Barts &amp;amp; The London NHS Trust.

Over 20,000 visitors in the last year</gtr:impact><gtr:outcomeId>AWvhtTw6oTt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM ambassador</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AF888B62-6F58-47C7-A9FA-11F1E15484A4</gtr:id><gtr:impact>Schools return every year for more. Many schools have said it makes a difference to childrens interest in STEM subjects.

Many schools have said it makes a difference to childrens interest in STEM subjects.</gtr:impact><gtr:outcomeId>bHQrdYtJYsn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Retrovirology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3DE2457-FF4E-4176-8066-CC55AF0B0396</gtr:id><gtr:impact>Lots of interest and feedback on my work

Bomed Central suggested they would comission a commentry on my work when it is published</gtr:impact><gtr:outcomeId>iooSYYmSjbJ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A technique was developed to identify restriction factors to replication of HIV in humans cells.</gtr:description><gtr:id>3354B6B7-3A98-4FEC-86AD-5FE14BC5EE55</gtr:id><gtr:impact>This took 1.5 years to establish a robust screening assay and can be applied to screen for other phenotypes.</gtr:impact><gtr:outcomeId>1CA78967DAC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Assay system for siRNA whole genome screening</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have recruited almost 400 patients from Barts and The London and Homerton Hospitals. The patients come from all over the world so the viruses are representative of the worldwide pandemic.</gtr:description><gtr:id>68C3464F-167C-46C1-B5AF-4746F5FA3856</gtr:id><gtr:impact>The patient B-cells are being used to isolate Neutralizing antibodies to HIV. The hope is that broadly neutralizing antibodies will be used to guide antigen design in vaccine research.</gtr:impact><gtr:outcomeId>6D34A958AE6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cohort of patients infected with diverse clades of HIV</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have now recruited about 80 patients who control HIV replication and/or disease. We have also identified a unique patient set who control viral replication but their CD4 cells continue to decline.</gtr:description><gtr:id>9EC117EC-CCB6-48D0-8C96-737ADEB35020</gtr:id><gtr:impact>This cohort of patients will enable the study of the correlates of protection from AIDS in humans. It will also be used in our studies of innate immune factors and HIV replication.</gtr:impact><gtr:outcomeId>6E421B10D29</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Elite suppressor cohort of HIV infected patients</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have identified 140 genes involved in the innate immune response against HIV.</gtr:description><gtr:id>D16ACFF1-64EF-4F17-B5C3-06EF5DB16EC5</gtr:id><gtr:impact>The factors identified are likely to apply to any viral infection and will considerable increase our knowledge of innate immunity to viruses.</gtr:impact><gtr:outcomeId>7C664C34BB2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>whole human genome screen for innate anti HIV factors</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3C363B16-F6C8-4B26-80ED-653B09F02827</gtr:id><gtr:title>CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd92b28501769abd41d6d2a3147773a9"><gtr:id>fd92b28501769abd41d6d2a3147773a9</gtr:id><gtr:otherNames>Endres MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>pm_12566_866_8929542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B37E557-35BA-4DF0-886F-E695E0E3DCDA</gtr:id><gtr:title>HIV-1 tropism and co-receptor use.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cedbff3198598ac844a35468fadb174"><gtr:id>8cedbff3198598ac844a35468fadb174</gtr:id><gtr:otherNames>Dittmar MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_12566_966_9020356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>773C77FB-272D-497A-9195-A2829C0FB1FB</gtr:id><gtr:title>RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ce528b88cb9daf3c603e35f240ba21c"><gtr:id>9ce528b88cb9daf3c603e35f240ba21c</gtr:id><gtr:otherNames>Marno KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d46b4dcba958.36015924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F684DFEA-4E34-4CB9-B959-8595C99B3C57</gtr:id><gtr:title>Development of HIV-1 group-specific neutralizing antibodies after seroconversion.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1992-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12566_166_1418776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0CD1CD9-F20C-4DB1-9B27-39D6805D39C6</gtr:id><gtr:title>Immune escape and tropism of HIV.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>pm_12566_866_8520889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC01108E-2179-448B-AA89-694381F81DD7</gtr:id><gtr:title>HIV Vaccine Approaches</gtr:title><gtr:parentPublicationTitle>Encyclopaedia of life Sciences (ELS), John Wiley &amp; Sons, Ltd</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/882c00b14bc152dc7eae3a20696ec4e6"><gtr:id>882c00b14bc152dc7eae3a20696ec4e6</gtr:id><gtr:otherNames>?ine McKnight</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>C96BB7E8C85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB3765DA-E828-432D-B65A-BB71FC5FDF3E</gtr:id><gtr:title>Lessons learned from humoral responses of HIV patients.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0143de37e46d8a91c66f83dee9425f2"><gtr:id>f0143de37e46d8a91c66f83dee9425f2</gtr:id><gtr:otherNames>McCoy LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>58b6e86aa7b7c1.35955487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3885A2F-15E7-4D61-A8CE-22F7D9BF1022</gtr:id><gtr:title>Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b4932442cbd866d01ac738a19974e3d"><gtr:id>6b4932442cbd866d01ac738a19974e3d</gtr:id><gtr:otherNames>Cheney KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>tJ9GKfbuyPM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>943488F9-262E-41A6-899C-E5C43D400BC6</gtr:id><gtr:title>Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity.</gtr:title><gtr:parentPublicationTitle>BMC immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0408219e3c9858a26fbabf37f2dea194"><gtr:id>0408219e3c9858a26fbabf37f2dea194</gtr:id><gtr:otherNames>Kelly BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2172</gtr:issn><gtr:outcomeId>QGn2T2kdmFV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F805F15-DC1D-45ED-80A5-26AE7EA3EC45</gtr:id><gtr:title>The evolution of structured illumination microscopy in studies of HIV.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb957f33d0efeda21f0b00809cf84e0"><gtr:id>aeb957f33d0efeda21f0b00809cf84e0</gtr:id><gtr:otherNames>Marno K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>56d43757b6f5d5.40103578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45BABE80-A639-4EE3-8663-3334C57A1D1E</gtr:id><gtr:title>Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display.</gtr:title><gtr:parentPublicationTitle>Human antibodies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f266c5de1e93507f08d86a8b7da2032d"><gtr:id>f266c5de1e93507f08d86a8b7da2032d</gtr:id><gtr:otherNames>Tang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1093-2607</gtr:issn><gtr:outcomeId>pm_12566_26_22885956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3566FAC2-7F9A-4ECC-B62A-A2D48C797EB6</gtr:id><gtr:title>A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5a independent.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/621dd7617d9b685d3ce7e3626e9fde68"><gtr:id>621dd7617d9b685d3ce7e3626e9fde68</gtr:id><gtr:otherNames>Oliveira NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>ZbzoNioHmEK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A57036C-8179-4789-998E-10D8A6B42D17</gtr:id><gtr:title>Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/868d3ebd4428b4b198dcb298c9047082"><gtr:id>868d3ebd4428b4b198dcb298c9047082</gtr:id><gtr:otherNames>Dreja H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>mjJj3B1tZrs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>337366F6-704E-4211-AFC0-A6C5A497198F</gtr:id><gtr:title>Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1b430cf4ad306ed94a8d1dceeb43bbd"><gtr:id>c1b430cf4ad306ed94a8d1dceeb43bbd</gtr:id><gtr:otherNames>Harrison IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>nXkWgi3GFpm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26DBCADA-7B20-48E1-AB33-9BD9CD64F217</gtr:id><gtr:title>A whole genome screen for HIV restriction factors.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b730bf7815eebc625c914f7f96b885cf"><gtr:id>b730bf7815eebc625c914f7f96b885cf</gtr:id><gtr:otherNames>Liu L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>TrgXgw5onms</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F03753-AF26-4A8E-A3B5-E7E92D20ECB8</gtr:id><gtr:title>CD26 antigen and HIV fusion?</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78f4dbab6e698d0b56ffce173f8fe2cf"><gtr:id>78f4dbab6e698d0b56ffce173f8fe2cf</gtr:id><gtr:otherNames>Patience C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_12566_766_7909960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E8696DB-F30F-4CEF-A08A-04B52ADFB905</gtr:id><gtr:title>Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0408219e3c9858a26fbabf37f2dea194"><gtr:id>0408219e3c9858a26fbabf37f2dea194</gtr:id><gtr:otherNames>Kelly BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5A403F63D1E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9ABAF67-81EA-4BFF-97A3-411A750D915D</gtr:id><gtr:title>Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0ea9cc5edd7a16475e01d3b4750239"><gtr:id>0f0ea9cc5edd7a16475e01d3b4750239</gtr:id><gtr:otherNames>Richards KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>NFHXnWiQKc7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E48EB57-3EDC-4250-BEC8-2A5093D036C4</gtr:id><gtr:title>HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands.</gtr:title><gtr:parentPublicationTitle>Molecular membrane biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/553e8eea58990ee86a0aa85fe35b1888"><gtr:id>553e8eea58990ee86a0aa85fe35b1888</gtr:id><gtr:otherNames>Clapham PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0968-7688</gtr:issn><gtr:outcomeId>pm_12566_16_10332737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DADF235-F4D3-4CA6-9602-2F9C9DB191B2</gtr:id><gtr:title>HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1994-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_12566_866_8178492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6268A72B-BE53-46DE-A45B-4FDA9F029600</gtr:id><gtr:title>Is CD4 sufficient for HIV entry? Cell surface molecules involved in HIV infection.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dea1742aa9d41f3a2140a346d2acea6e"><gtr:id>dea1742aa9d41f3a2140a346d2acea6e</gtr:id><gtr:otherNames>Clapham P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>pm_12566_766_7904349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23CF0529-0739-4C72-897E-6C17928EAD3E</gtr:id><gtr:title>In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606c1ab317e343afbff57b6a1a7a52e8"><gtr:id>606c1ab317e343afbff57b6a1a7a52e8</gtr:id><gtr:otherNames>Aasa-Chapman MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>aSXWE1QzyB1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A089594-5674-4D82-8A7F-92643D38276D</gtr:id><gtr:title>Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c527c84b5538210ff68b0451081c102"><gtr:id>2c527c84b5538210ff68b0451081c102</gtr:id><gtr:otherNames>Reeves JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12566_16_10438870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B740DCDA-B24F-44DD-93B7-0EA1A4812654</gtr:id><gtr:title>HIV.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>pm_12566_16_10209129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8298191E-D3E7-42A8-9518-BE24B5CD72A0</gtr:id><gtr:title>Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>L2vdWuKReac</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03C2F6CB-1A4F-4BB2-88E8-B9EB092E5D7A</gtr:id><gtr:title>CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c527c84b5538210ff68b0451081c102"><gtr:id>2c527c84b5538210ff68b0451081c102</gtr:id><gtr:otherNames>Reeves JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1997-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_12566_966_9143311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>322D8F8C-56A5-4730-A3BC-8364D3D1B502</gtr:id><gtr:title>Studies on the immunogenicity of Chinese hamster ovary cell-derived recombinant gp120 (HIV-1IIIB).</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1991-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_12566_266_2008801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>870A1021-EE76-43A1-9C07-3EA744A6C421</gtr:id><gtr:title>Human PAF1 inhibition of HIV-1</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dfa15fee77343eae01dc5483284c1a3"><gtr:id>0dfa15fee77343eae01dc5483284c1a3</gtr:id><gtr:otherNames>Alonso A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_12566__10_S1_P39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>549289A7-F083-406E-8AAA-B9723D4DF730</gtr:id><gtr:title>Cell-to-cell fusion, but not virus entry in macrophages by T-cell line tropic HIV-1 strains: a V3 loop-determined restriction.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd6fca5153f26d1eff225fa6decc633b"><gtr:id>dd6fca5153f26d1eff225fa6decc633b</gtr:id><gtr:otherNames>Simmons G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1995-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_12566_766_7778305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C8AF81A-BEFE-448F-BFFE-A9219099F352</gtr:id><gtr:title>Investigating early events in HIV-1 replication: the role of envelope signalling and PAF1 restriction factor</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94644620134911467d28f22ddf29b402"><gtr:id>94644620134911467d28f22ddf29b402</gtr:id><gtr:otherNames>Ana Guerrero Alonso</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56d46a77093e67.31259207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0888FDC-E098-47A4-ABFD-384B15D9E282</gtr:id><gtr:title>HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5903a122d10f8eb021e2f214a79721f"><gtr:id>c5903a122d10f8eb021e2f214a79721f</gtr:id><gtr:otherNames>Durda PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_12566_166_1702301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E56E8715-FF6C-4EBD-A964-582AF5016C1C</gtr:id><gtr:title>Clade specific neutralising vaccines for HIV: an appropriate target?</gtr:title><gtr:parentPublicationTitle>Current HIV research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1570-162X</gtr:issn><gtr:outcomeId>E65DFEDBBC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E558DCE-82C8-4576-BCAD-7E759F094FA3</gtr:id><gtr:title>Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c192d8ff6e58b9d307bb0cab17640e26"><gtr:id>c192d8ff6e58b9d307bb0cab17640e26</gtr:id><gtr:otherNames>Koh WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>Zn8jrpQeqKd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C89F10D-F6A2-4699-868C-7C4E6CD434E6</gtr:id><gtr:title>CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/868d3ebd4428b4b198dcb298c9047082"><gtr:id>868d3ebd4428b4b198dcb298c9047082</gtr:id><gtr:otherNames>Dreja H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56d437bd573012.27756438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8C934AE-35E6-44FF-85BA-4A2CF0EAF4A2</gtr:id><gtr:title>Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d0bd6d3bfa5b2334a6e34ce84243736"><gtr:id>4d0bd6d3bfa5b2334a6e34ce84243736</gtr:id><gtr:otherNames>Marchant D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>51A36585ECE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F1A52B-BF13-47B0-AF3C-312FE347E13B</gtr:id><gtr:title>Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb957f33d0efeda21f0b00809cf84e0"><gtr:id>aeb957f33d0efeda21f0b00809cf84e0</gtr:id><gtr:otherNames>Marno K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_12566__10_S1_P57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E441AEBF-6569-4A53-A316-90A0AE1D1778</gtr:id><gtr:title>Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc8ffba70836fab182edc4706d6913a"><gtr:id>7cc8ffba70836fab182edc4706d6913a</gtr:id><gtr:otherNames>Schutten M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1993-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12566_766_7689324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22AF2EE9-8271-4405-BE22-0B0DD6D662C7</gtr:id><gtr:title>Disease Progression in HIV-1-Infected Viremic Controllers.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8947224e49a15de2487160fc22725476"><gtr:id>8947224e49a15de2487160fc22725476</gtr:id><gtr:otherNames>Groves KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12566_26_22902723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB35CCF1-CC34-4089-8346-A45FECCE4235</gtr:id><gtr:title>Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a451bf1b348d74a82a3f39eded8f8a"><gtr:id>93a451bf1b348d74a82a3f39eded8f8a</gtr:id><gtr:otherNames>Forsman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>290AE17096D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DFA6A6B-AD8E-4CF9-AC72-FA830942AFD8</gtr:id><gtr:title>Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606c1ab317e343afbff57b6a1a7a52e8"><gtr:id>606c1ab317e343afbff57b6a1a7a52e8</gtr:id><gtr:otherNames>Aasa-Chapman MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>373AEE48A83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39F779F2-9BCB-4CE3-82C0-3375028331F7</gtr:id><gtr:title>Managing HIV. Part 7: Professional issues. 7.4 HIV and complementary medicine.</gtr:title><gtr:parentPublicationTitle>The Medical journal of Australia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86fcf65e31bd987c6c52ea920653cf97"><gtr:id>86fcf65e31bd987c6c52ea920653cf97</gtr:id><gtr:otherNames>McKnight I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:issn>0025-729X</gtr:issn><gtr:outcomeId>pm_12566_866_8709877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96420C86-B36A-44C3-A028-4962B19EC92B</gtr:id><gtr:title>Novel envelope determinants for CCR3 use by human immunodeficiency virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606c1ab317e343afbff57b6a1a7a52e8"><gtr:id>606c1ab317e343afbff57b6a1a7a52e8</gtr:id><gtr:otherNames>Aasa-Chapman MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>9EADCE7F6B1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G117/547</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>